Hiroki Ishii

Hiroki Ishii

Auto-generated profile, based on publicly available information

Hiroki Ishii

Division of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2021 in Frontiers in Medicine
Verified
Journal Article
Open access
KHKeiji Hirai
Keiji Hirai
HNHiroaki Nonaka
Hiroaki Nonaka
MUMoeka Ueda
Moeka Ueda
JMJunki Morino
Junki Morino
SKShohei Kaneko
Shohei Kaneko
Yoshiyuki MorishitaYoshiyuki Morishita
Yoshiyuki Morishita
Background: We investigated the effects of roxadustat on the anemia, iron metabolism, peritoneal membrane function, and residual renal function; and determined the factors associated with the administration of roxadustat in patients who were undergoing peritoneal dialysis.Methods: We retrospectively analyzed the changes in hemoglobin, serum ferritin, transferrin saturation (TSAT), 4-h dialysate/plasma creatinine, and renal weekly urea clearance over the 24 weeks following the change from an erythropoiesis-stimulating agent (ESA) to roxadustat in 16 patients who were undergoing peritoneal dialysis and had anemia (Roxadustat group). Twenty-three peritoneal dialysis patients who had anemia and continued ESA served as a control group (ESA group).Results: There were no significant differences in hemoglobin, serum ferritin, TSAT, 4-h dialysate/plasma creatinine, or renal weekly urea clearance between the two groups at baseline. The hemoglobin concentration was significantly higher in the Roxadustat group than in the ESA group after 24 weeks (11.6 ± 1.0 g/dL vs. 10.3 ± 1.1 g/dL, p < 0.05), whereas the ferritin concentration and TSAT were significantly lower (139.5 ± 102.0 ng/mL vs. 209.2 ± 113.1 ng/mL, p < 0.05; and 28.1 ± 11.5% vs. 44.8 ± 10.4%, p < 0.05, respectively). The changes in 4-h dialysate/plasma creatinine and renal weekly urea clearance did not differ between the two groups. Linear regression analysis revealed that the serum potassium concentration correlated with the dose of roxadustat at 24 weeks (standard coefficient = 0.580, p = 0.019).Conclusion: Roxadustat may improve the anemia and reduce the serum ferritin and TSAT of the peritoneal dialysis patients after they were switched from an ESA, without association with peritoneal membrane function or residual renal function.

30 September 2019 in Kidney Research and Clinical Practice
Verified
Journal Article
Open access
KHKeiji Hirai
Keiji Hirai
SMSaori Minato
Saori Minato
SKShohei Kaneko
Shohei Kaneko
KYKatsunori Yanai
Katsunori Yanai
HIHiroki Ishii
Hiroki Ishii
Yoshiyuki MorishitaYoshiyuki Morishita
Yoshiyuki Morishita
Background: We investigated the relationship between serum total carbon dioxide (CO2) and bicarbonate ion (HCO3-) concentrations in pre-dialysis chronic kidney disease (CKD) patients and devised a formula for predicting low bicarbonate (HCO3- < 24 mmol/L) and high bicarbonate (HCO3- >= 24 mmol/L) using clinical parameters. Methods: In total, 305 samples of venous blood collected from 207 pre-dialysis patients assessed by CKD stage (G1 + G2, 46; G3, 50; G4, 51; G5, 60) were investigated. The relationship between serum total CO2 and HCO3- concentrations was analyzed using Pearson's correlation coefficient. An approximation formula was developed using clinical parameters correlated independently with HCO3- concentration. Diagnostic accuracy of serum total CO2 and the approximation formula was evaluated by receiver operating characteristic curve analysis and a 2 x 2 table. Results: Serum total CO2 correlated strongly with HCO3- concentration (r = 0.91; P < 0.001). The following approximation formula was obtained by a multiple linear regression analysis: HCO3- (mmol/L) = total CO2- 0.5 x albumin - 0.1 x chloride - 0.01 x (estimated glomerular filtration rate + blood glucose) + 15. The areas under the curves of serum total CO2 and the approximation formula for detection of low bicarbonate and high bicarbonate were 0.981, 0.996, 0.993, and 1.000, respectively. This formula had superior diagnostic accuracy compared with that of serum total CO2 (86.6% vs. 81.3%). Conclusion: Serum total CO2 correlated strongly with HCO3- concentration in pre-dialysis CKD patients. An approximation formula including serum total CO2 showed superior diagnostic accuracy for low and high bicarbonate compared with serum total CO2.

24 July 2019 in Journal of Artificial Organs
Verified
Journal Article
Closed access
PDF file
SMSaori Minato
Saori Minato
SOSusumu Ookawara
Susumu Ookawara
KIKiyonori Ito
Kiyonori Ito
HMHaruhisa Miyazawa
Haruhisa Miyazawa
HHHideyuki Hayasaka
Hideyuki Hayasaka
Yoshiyuki MorishitaYoshiyuki Morishita
Yoshiyuki Morishita

1 January 2020 in International Journal of Nephrology and Renovascular Disease
Verified
Journal Article
Open access
PDF file
SMSaori Minato
Saori Minato
KHKeiji Hirai
Keiji Hirai
JMJunki Morino
Junki Morino
SKShohei Kaneko
Shohei Kaneko
KYKatsunori Yanai
Katsunori Yanai
YMYoshiyuki Morishita
Yoshiyuki Morishita
Aim: The aim of this study was to investigate different intensities of uremic pruritus in the daytime and nighttime, as well as contributing factors, in patients undergoing peritoneal dialysis (PD). Methods: A total of 46 patients (31 males, 15 females) with a mean age of 59.4± 14.7 years and mean PD vintage of 29.2± 25.2 months were enrolled in this single-center, prospective, cross-sectional study. The intensity of uremic pruritus in the daytime and nighttime was assessed using a visual analog scale (VAS). The relationships between intensity and various clinical and laboratory parameters were analyzed using multiple linear regression analyses. Results: The most common site of uremic pruritus was on the back (70%), followed by lower limbs (67%), chest and abdomen (59%), upper limbs (28%), and head and neck (22%). Mean VAS scores were higher in the nighttime compared with the daytime (4.5± 3.3 vs. 3.5± 2.7, P=0.02). Only male sex was correlated with higher uremic pruritus intensity in the daytime (standard coefficient [β]=0.310, P=0.036). PD vintage (β=0.415, P=0.004) and topical medicines, including moisturizer and topical corticosteroid use (β=0.345, P=0.019), were independently correlated with higher uremic pruritus intensity in the nighttime. Conclusion: Uremic pruritus intensity was greater in the nighttime than in the daytime in PD patients. Male sex was associated with higher uremic pruritus intensity in the daytime, whereas PD vintage and topical medicine use were associated with higher uremic pruritus intensity in the nighttime.

31 December 2020 in Kidney Research and Clinical Practice
Verified
Journal Article
Open access
PDF file
KHKeiji Hirai
Keiji Hirai
SOSusumu Ookawara
Susumu Ookawara
JMJunki Morino
Junki Morino
SMSaori Minato
Saori Minato
SKShohei Kaneko
Shohei Kaneko
Yoshiyuki MorishitaYoshiyuki Morishita
Yoshiyuki Morishita
Keiji Hirai, Susumu Ookawara, Junki Morino, Saori Minato, Shohei Kaneko, Katsunori Yanai, Hiroki Ishii, Momoko Matsuyama, Taisuke Kitano, Mitsutoshi Shindo, Haruhisa Miyazawa, Kiyonori Ito, Yuichirou Ueda, Tatsuro Watano, Shinji Fujino, Kiyoka Omoto, Yoshiyuki Morishita. Kidney Research and Clinical Practice 2020;39:441-50. https://doi.org/10.23876/j.krcp.19.126

1 January 2020 in Diabetes, Metabolic Syndrome and Obesity
Verified
Journal Article
Open access
PDF file
KHKeiji Hirai
Keiji Hirai
JMJunki Morino
Junki Morino
SMSaori Minato
Saori Minato
SKShohei Kaneko
Shohei Kaneko
KYKatsunori Yanai
Katsunori Yanai
YMYoshiyuki Morishita
Yoshiyuki Morishita
Introduction and Objectives: We investigated the efficacy and safety of sodium-glucose cotransporter-2 (SGLT-2) inhibitors as an add-on therapy in patients with advanced-stage diabetic kidney disease taking renin-angiotensin system (RAS) blockers. Materials and Methods: Changes in glycated hemoglobin (HbA1c), urine protein-to-creatinine ratio (UACR), body weight, systolic blood pressure, and annual change in estimated glomerular filtration rate (eGFR) were retrospectively analyzed in 20 patients after 12 months of SGLT-2 inhibitor administration (mean eGFR: 22.8 ± 9.7 mL/min/1.73 m2). All patients had advanced-stage diabetic kidney disease and were taking RAS blockers. Twenty patients matched with similar propensity scores who were not taking SGLT-2 inhibitors served as the control group. Results: The annual change in eGFR improved significantly from − 8.6 ± 12.5 mL/min/1.73 m2/year to − 2.6 ± 5.0 mL/min/1.73 m2/year after 12 months by SGLT-2 inhibitor administration (p < 0.05), but did not change in the control group. Other clinical parameters, such as HbA1c, UACR, body weight, blood pressure, serum lipids, and electrolytes did not change in either group. No adverse effects were observed by taking SGLT-2 inhibitors. Conclusion: Using SGLT-2 inhibitors as an add-on therapy may have beneficial effects on renal function in patients with advanced-stage diabetic kidney disease taking RAS blockers without any adverse effects.